Meet us at EBMT
Meet our medical team to find out more about our clinical program and CAR-T cell therapies on April 14-17, 2024 in Glasgow, Scotland, UK
Meet us at EBMT
Meet our medical team to find out more about our clinical program and CAR-T cell therapies on April 14-17, 2024 in Glasgow, Scotland, UK
We are looking forward to your visit during EBMT
We are excited to be present at the #EBMT24 Congress, April 14-17 in Glasgow, Scotland. We look forward to welcoming you to our booth (E11), where you will be able to speak to our medical team about our clinical program and open trials. Check out this web page to see what we can discuss with you in Glasgow.
#EBMT24 will take place at the SCOTTISH EVENT CAMPUS (SEC Centre) Glasgow, Scotland, G3 8YW The United Kingdom. You will find us at the Miltenyi Biomedicine booth E11.
Exhibition opening hours:
April 14-16, 9:00 a.m. - 5:00 p.m.
April 17, 9:00 a.m. - 1:00 p.m.
See the detailed program 50th Annual Meeting of the EBMT
Check the #EBMT24 program hereLatest resources and news about Miltenyi Biomedicine presented at #EBMT24
DALY 2-EU trial –
now recruiting
Visit official trial page
Latest resources from Miltenyi Biomedicine
View recent posters, presentations and press releases
Miltenyi Biomedicine will present new data from the DALY 2-EU study at the American Society of Hematology (ASH) Annual Meeting
ASH 2025 | press release
Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)
Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR | presentation slides
Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (zamto-cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
ASH24 | presentation slides
Miltenyi Biomedicine will share positive interim results from DALY II USA at the American Society of Hematology (ASH) Annual Meeting
ASH 2024 | press release
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR-T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract
